Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
A method of determining whether a patient diagnosed with HER2 positive breast cancer is more or less suitably treated by an anti-cancer therapy comprising an anti-VEGF antibody, the method comprising: (a) determining an expression level of VEGFA and/or VEGFR2 in a sample derived from a patient diagn...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | KARL JOHANN DE HAAS SANNE LYSBET MENG YU-JU GLORIA ELLIOTT REBECCA PLOWMAN GREGORY D WILD NORBERT SCHERER STEFAN ANDRES HERBERT |
| description | A method of determining whether a patient diagnosed with HER2 positive breast cancer is more or less suitably treated by an anti-cancer therapy comprising an anti-VEGF antibody, the method comprising: (a) determining an expression level of VEGFA and/or VEGFR2 in a sample derived from a patient diagnosed with HER2 positive breast cancer, and (b) identifying the patient as more or less suitably treated by an anti-cancer therapy comprising an anti-VEGF antibody based on the expression level in accordance with (a), wherein an expression level of VEGFA and/or VEGFR2 at or above a reference level indicates that the patient is more suitably treated with the anti-cancer therapy, or an expression level of VEGFA and/or VEGFR2 below a reference level indicates that the patient is less suitably treated with the anti-cancer therapy. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_NZ624444A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>NZ624444A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_NZ624444A3</originalsourceid><addsrcrecordid>eNqFijEKQjEQBdNYiHoF2QvYqNirKFZWViJ8NvEFw0-yIVktPL0ftHeaYWDG5raLIncqkVtiskES1x61kZdKFi924f1MbMlJsiGzBsmkD1QuAd9LK1gTspJ4skM0JcfZoU7NyHNsmP08MfPj4bI_LVCkQyvskKHd-bpZrge2q7_DB5cTOz0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer</title><source>esp@cenet</source><creator>KARL JOHANN ; DE HAAS SANNE LYSBET ; MENG YU-JU GLORIA ; ELLIOTT REBECCA ; PLOWMAN GREGORY D ; WILD NORBERT ; SCHERER STEFAN ; ANDRES HERBERT</creator><creatorcontrib>KARL JOHANN ; DE HAAS SANNE LYSBET ; MENG YU-JU GLORIA ; ELLIOTT REBECCA ; PLOWMAN GREGORY D ; WILD NORBERT ; SCHERER STEFAN ; ANDRES HERBERT</creatorcontrib><description>A method of determining whether a patient diagnosed with HER2 positive breast cancer is more or less suitably treated by an anti-cancer therapy comprising an anti-VEGF antibody, the method comprising: (a) determining an expression level of VEGFA and/or VEGFR2 in a sample derived from a patient diagnosed with HER2 positive breast cancer, and (b) identifying the patient as more or less suitably treated by an anti-cancer therapy comprising an anti-VEGF antibody based on the expression level in accordance with (a), wherein an expression level of VEGFA and/or VEGFR2 at or above a reference level indicates that the patient is more suitably treated with the anti-cancer therapy, or an expression level of VEGFA and/or VEGFR2 below a reference level indicates that the patient is less suitably treated with the anti-cancer therapy.</description><language>eng</language><subject>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES ; MEASURING ; PHYSICS ; TESTING</subject><creationdate>2016</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20160729&DB=EPODOC&CC=NZ&NR=624444A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20160729&DB=EPODOC&CC=NZ&NR=624444A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>KARL JOHANN</creatorcontrib><creatorcontrib>DE HAAS SANNE LYSBET</creatorcontrib><creatorcontrib>MENG YU-JU GLORIA</creatorcontrib><creatorcontrib>ELLIOTT REBECCA</creatorcontrib><creatorcontrib>PLOWMAN GREGORY D</creatorcontrib><creatorcontrib>WILD NORBERT</creatorcontrib><creatorcontrib>SCHERER STEFAN</creatorcontrib><creatorcontrib>ANDRES HERBERT</creatorcontrib><title>Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer</title><description>A method of determining whether a patient diagnosed with HER2 positive breast cancer is more or less suitably treated by an anti-cancer therapy comprising an anti-VEGF antibody, the method comprising: (a) determining an expression level of VEGFA and/or VEGFR2 in a sample derived from a patient diagnosed with HER2 positive breast cancer, and (b) identifying the patient as more or less suitably treated by an anti-cancer therapy comprising an anti-VEGF antibody based on the expression level in accordance with (a), wherein an expression level of VEGFA and/or VEGFR2 at or above a reference level indicates that the patient is more suitably treated with the anti-cancer therapy, or an expression level of VEGFA and/or VEGFR2 below a reference level indicates that the patient is less suitably treated with the anti-cancer therapy.</description><subject>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</subject><subject>MEASURING</subject><subject>PHYSICS</subject><subject>TESTING</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2016</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqFijEKQjEQBdNYiHoF2QvYqNirKFZWViJ8NvEFw0-yIVktPL0ftHeaYWDG5raLIncqkVtiskES1x61kZdKFi924f1MbMlJsiGzBsmkD1QuAd9LK1gTspJ4skM0JcfZoU7NyHNsmP08MfPj4bI_LVCkQyvskKHd-bpZrge2q7_DB5cTOz0</recordid><startdate>20160729</startdate><enddate>20160729</enddate><creator>KARL JOHANN</creator><creator>DE HAAS SANNE LYSBET</creator><creator>MENG YU-JU GLORIA</creator><creator>ELLIOTT REBECCA</creator><creator>PLOWMAN GREGORY D</creator><creator>WILD NORBERT</creator><creator>SCHERER STEFAN</creator><creator>ANDRES HERBERT</creator><scope>EVB</scope></search><sort><creationdate>20160729</creationdate><title>Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer</title><author>KARL JOHANN ; DE HAAS SANNE LYSBET ; MENG YU-JU GLORIA ; ELLIOTT REBECCA ; PLOWMAN GREGORY D ; WILD NORBERT ; SCHERER STEFAN ; ANDRES HERBERT</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_NZ624444A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2016</creationdate><topic>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</topic><topic>MEASURING</topic><topic>PHYSICS</topic><topic>TESTING</topic><toplevel>online_resources</toplevel><creatorcontrib>KARL JOHANN</creatorcontrib><creatorcontrib>DE HAAS SANNE LYSBET</creatorcontrib><creatorcontrib>MENG YU-JU GLORIA</creatorcontrib><creatorcontrib>ELLIOTT REBECCA</creatorcontrib><creatorcontrib>PLOWMAN GREGORY D</creatorcontrib><creatorcontrib>WILD NORBERT</creatorcontrib><creatorcontrib>SCHERER STEFAN</creatorcontrib><creatorcontrib>ANDRES HERBERT</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>KARL JOHANN</au><au>DE HAAS SANNE LYSBET</au><au>MENG YU-JU GLORIA</au><au>ELLIOTT REBECCA</au><au>PLOWMAN GREGORY D</au><au>WILD NORBERT</au><au>SCHERER STEFAN</au><au>ANDRES HERBERT</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer</title><date>2016-07-29</date><risdate>2016</risdate><abstract>A method of determining whether a patient diagnosed with HER2 positive breast cancer is more or less suitably treated by an anti-cancer therapy comprising an anti-VEGF antibody, the method comprising: (a) determining an expression level of VEGFA and/or VEGFR2 in a sample derived from a patient diagnosed with HER2 positive breast cancer, and (b) identifying the patient as more or less suitably treated by an anti-cancer therapy comprising an anti-VEGF antibody based on the expression level in accordance with (a), wherein an expression level of VEGFA and/or VEGFR2 at or above a reference level indicates that the patient is more suitably treated with the anti-cancer therapy, or an expression level of VEGFA and/or VEGFR2 below a reference level indicates that the patient is less suitably treated with the anti-cancer therapy.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_NZ624444A |
| source | esp@cenet |
| subjects | INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING PHYSICS TESTING |
| title | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T21%3A48%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=KARL%20JOHANN&rft.date=2016-07-29&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ENZ624444A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |